pirinixic acid has been researched along with Insulin Resistance in 22 studies
pirinixic acid: structure
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " By activating PPARα, the lipid-lowering drug fenofibrate reverses dyslipidemia and improves insulin sensitivity in type 2 diabetes in part by promoting fatty acid oxidation." | 7.83 | Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity. ( Ghanem, SS; Heinrich, G; Najjar, SM; Oyarce, AM; Patel, PR; Ramakrishnan, SK; Russo, L, 2016) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| " By activating PPARα, the lipid-lowering drug fenofibrate reverses dyslipidemia and improves insulin sensitivity in type 2 diabetes in part by promoting fatty acid oxidation." | 3.83 | Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity. ( Ghanem, SS; Heinrich, G; Najjar, SM; Oyarce, AM; Patel, PR; Ramakrishnan, SK; Russo, L, 2016) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| "We investigated the effects of acute (24-h) peroxisome proliferator-activated receptor (PPAR)alpha activation by WY14,643 (pirinixic acid) treatment on glucose-stimulated insulin secretion (GSIS) during pregnancy, in the rat, in relation to insulin sensitivity." | 3.72 | Peroxisome proliferator-activated receptor-alpha activation during pregnancy attenuates glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, without impairing pregnancy-induced increases in beta-cell glucose sensing and res ( Greenwood, GK; Holness, MJ; Smith, ND; Sugden, MC, 2003) |
| "PPAR-alpha activation reduced BM and treated insulin resistance (IR) and NAFLD by increasing the number of mitochondria and reducing hepatic gluconeogenesis and de novo lipogenesis protein and gene expressions in a murine obesity model." | 1.46 | Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice. ( Barreto, AB; Graus-Nunes, F; Mandarim-de-Lacerda, CA; Rachid, TL; Souza-Mello, V; Veiga, FMS, 2017) |
| "Insulin resistance is the failure of insulin to stimulate the transport of glucose into its target cells." | 1.35 | Nuclear receptor agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture. ( Lerch, R; Montessuit, C; Papageorgiou, I, 2008) |
| "Moreover, Wy-14,643 treatment reduced inflammation and the expression of macrophage-specific genes in white adipose tissue (WAT)." | 1.33 | Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. ( Hada, Y; Ito, Y; Kadowaki, T; Maki, T; Takekawa, S; Tsuchida, A; Yamauchi, T, 2005) |
| " The two PPAR-alpha activators, fenofibrate and Wy-14643, were dosed at different concentrations in high-fat fed Sprague-Dawley rats, and the transcriptional responses were examined in liver using cDNA microarrays." | 1.32 | Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. ( Fleckner, J; Frederiksen, KS; Sauerberg, P; Wassermann, K; Wulf, EM, 2003) |
| "(-)DRF 2725 (6) is a phenoxazine analogue of phenyl propanoic acid." | 1.31 | (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. ( Bajji, AC; Chakrabarti, R; Juluri, S; Kalchar, S; Lohray, BB; Lohray, VB; Mamidi, NV; Misra, P; Padakanti, S; Poondra, RR; Rajagopalan, R; Vikramadithyan, RK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (59.09) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Lohray, BB | 1 |
| Lohray, VB | 1 |
| Bajji, AC | 1 |
| Kalchar, S | 1 |
| Poondra, RR | 1 |
| Padakanti, S | 1 |
| Chakrabarti, R | 1 |
| Vikramadithyan, RK | 1 |
| Misra, P | 1 |
| Juluri, S | 1 |
| Mamidi, NV | 1 |
| Rajagopalan, R | 1 |
| Porcelli, L | 1 |
| Gilardi, F | 2 |
| Laghezza, A | 3 |
| Piemontese, L | 3 |
| Mitro, N | 1 |
| Azzariti, A | 1 |
| Altieri, F | 1 |
| Cervoni, L | 1 |
| Fracchiolla, G | 1 |
| Giudici, M | 1 |
| Guerrini, U | 1 |
| Lavecchia, A | 3 |
| Montanari, R | 1 |
| Di Giovanni, C | 1 |
| Paradiso, A | 1 |
| Pochetti, G | 1 |
| Simone, GM | 1 |
| Tortorella, P | 3 |
| Crestani, M | 1 |
| Loiodice, F | 3 |
| Cerchia, C | 2 |
| Ziccardi, P | 1 |
| Sblano, S | 2 |
| Iacobazzi, V | 1 |
| Infantino, V | 1 |
| Convertini, P | 1 |
| Dal Piaz, F | 1 |
| Lupo, A | 1 |
| Colantuoni, V | 1 |
| Brunetti, L | 1 |
| Leuci, R | 1 |
| Thomas, A | 1 |
| Genovese, M | 1 |
| Santi, A | 1 |
| Paoli, P | 1 |
| Veiga, FMS | 1 |
| Graus-Nunes, F | 1 |
| Rachid, TL | 1 |
| Barreto, AB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Souza-Mello, V | 1 |
| Lebrun, V | 1 |
| Molendi-Coste, O | 1 |
| Lanthier, N | 1 |
| Sempoux, C | 1 |
| Cani, PD | 1 |
| van Rooijen, N | 1 |
| Stärkel, P | 1 |
| Horsmans, Y | 1 |
| Leclercq, IA | 1 |
| Ramakrishnan, SK | 1 |
| Russo, L | 1 |
| Ghanem, SS | 1 |
| Patel, PR | 1 |
| Oyarce, AM | 1 |
| Heinrich, G | 1 |
| Najjar, SM | 1 |
| Holness, MJ | 3 |
| Greenwood, GK | 3 |
| Smith, ND | 3 |
| Sugden, MC | 3 |
| Oberkofler, H | 1 |
| Pfeifenberger, A | 1 |
| Soyal, S | 1 |
| Felder, T | 1 |
| Hahne, P | 1 |
| Miller, K | 1 |
| Krempler, F | 1 |
| Patsch, W | 1 |
| Larter, CZ | 1 |
| Yeh, MM | 1 |
| Van Rooyen, DM | 1 |
| Brooling, J | 1 |
| Ghatora, K | 1 |
| Farrell, GC | 1 |
| Funai, K | 1 |
| Song, H | 1 |
| Yin, L | 1 |
| Lodhi, IJ | 1 |
| Wei, X | 1 |
| Yoshino, J | 1 |
| Coleman, T | 2 |
| Semenkovich, CF | 2 |
| Ye, JM | 1 |
| Iglesias, MA | 1 |
| Watson, DG | 1 |
| Ellis, B | 1 |
| Wood, L | 1 |
| Jensen, PB | 1 |
| Sørensen, RV | 1 |
| Larsen, PJ | 1 |
| Cooney, GJ | 1 |
| Wassermann, K | 2 |
| Kraegen, EW | 1 |
| Frederiksen, KS | 1 |
| Wulf, EM | 1 |
| Sauerberg, P | 1 |
| Fleckner, J | 1 |
| Tsuchida, A | 1 |
| Yamauchi, T | 1 |
| Takekawa, S | 1 |
| Hada, Y | 1 |
| Ito, Y | 1 |
| Maki, T | 1 |
| Kadowaki, T | 1 |
| Cai, ZF | 1 |
| Liu, Q | 2 |
| Li, PP | 2 |
| Guo, ZR | 1 |
| Shen, ZF | 2 |
| Shan, S | 1 |
| Chen, YT | 1 |
| Ning, ZQ | 1 |
| Sun, SJ | 1 |
| Lu, XP | 1 |
| Xie, MZ | 1 |
| Sheikh, K | 1 |
| Camejo, G | 1 |
| Lanne, B | 1 |
| Halvarsson, T | 1 |
| Landergren, MR | 1 |
| Oakes, ND | 1 |
| Montessuit, C | 1 |
| Papageorgiou, I | 1 |
| Lerch, R | 1 |
| Tordjman, K | 1 |
| Bernal-Mizrachi, C | 1 |
| Zemany, L | 1 |
| Weng, S | 1 |
| Feng, C | 1 |
| Zhang, F | 1 |
| Leone, TC | 1 |
| Kelly, DP | 1 |
| Chou, CJ | 1 |
| Haluzik, M | 1 |
| Gregory, C | 1 |
| Dietz, KR | 1 |
| Vinson, C | 1 |
| Gavrilova, O | 1 |
| Reitman, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome[NCT02122666] | 100 participants (Anticipated) | Observational | 2014-03-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 other studies available for pirinixic acid and Insulin Resistance
| Article | Year |
|---|---|
(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
Topics: Animals; Biological Availability; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Hyperlip | 2001 |
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentia | 2012 |
New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
Topics: Antineoplastic Agents; Benzhydryl Compounds; beta Catenin; Carnitine; Cell Proliferation; Drug Evalu | 2017 |
A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
Topics: Cheminformatics; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands | 2022 |
Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice.
Topics: Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Dietary Fats; fas Receptor; Ge | 2017 |
Impact of PPAR-α induction on glucose homoeostasis in alcohol-fed mice.
Topics: Alcohol Drinking; Animals; Blood Glucose; Clodronic Acid; Fatty Liver; Female; Glucose; Homeostasis; | 2013 |
Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity.
Topics: Animals; Carcinoembryonic Antigen; Fenofibrate; Insulin; Insulin Resistance; Insulin Secretion; Mice | 2016 |
PPARalpha activation and increased dietary lipid oppose thyroid hormone signaling and rescue impaired glucose-stimulated insulin secretion in hyperthyroidism.
Topics: Animals; Anticholesteremic Agents; Antithyroid Agents; Dietary Fats; Eating; Female; Glucose; Glucos | 2008 |
Aberrant hepatic TRIB3 gene expression in insulin-resistant obese humans.
Topics: Carrier Proteins; Cell Cycle Proteins; Gene Expression; Heat-Shock Proteins; Hep G2 Cells; Humans; I | 2010 |
Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Topics: Adipose Tissue; Animals; Blotting, Western; Chemokine CCL2; Diabetes Mellitus; Disease Models, Anima | 2012 |
Muscle lipogenesis balances insulin sensitivity and strength through calcium signaling.
Topics: Adenylate Kinase; Animals; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Ce | 2013 |
Peroxisome proliferator-activated receptor-alpha activation during pregnancy attenuates glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, without impairing pregnancy-induced increases in beta-cell glucose sensing and res
Topics: Animals; Blood Glucose; Eating; Fatty Acids, Nonesterified; Female; Food; Glucose; Insulin; Insulin | 2003 |
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Topics: Animals; Dietary Fats; Fatty Liver; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; L | 2003 |
Acute (24 h) activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) reverses high-fat feeding-induced insulin hypersecretion in vivo and in perifused pancreatic islets.
Topics: Animals; Culture Techniques; Dietary Fats; Female; Glucose; Injections, Intravenous; Insulin; Insuli | 2003 |
Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists.
Topics: Animals; Blotting, Western; Fenofibrate; Insulin Resistance; Liver; Pyrimidines; Rats; Rats, Sprague | 2003 |
Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
Topics: Animals; Blood Glucose; Epididymis; Glucose Tolerance Test; Hypoglycemic Agents; Inflammation; Insul | 2005 |
Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid.
Topics: Animals; Arylsulfonates; Blood Glucose; Bone Neoplasms; Cell Line, Tumor; Glucose Tolerance Test; Hu | 2006 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat.
Topics: Amino Acids; Animal Feed; Animals; Chromatography, High Pressure Liquid; Dietary Fats; Dyslipidemias | 2007 |
Nuclear receptor agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture.
Topics: Alitretinoin; AMP-Activated Protein Kinase Kinases; Animals; Cells, Cultured; Cytoskeleton; Glucose; | 2008 |
PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice.
Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Blood Pressure; CD36 Antigens; Chemokine CCL2; | 2001 |
WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.
Topics: Acetyl-CoA Carboxylase; Animals; Blood Glucose; Diabetes Mellitus, Lipoatrophic; Fatty Acids, Nonest | 2002 |